Most anticancer drugs are characterised by a steep dose–response relationship and narrow
therapeutic window. Inter-individual pharmacokinetic (PK) variability is often substantial. The …

Optimising the dosing of medicines for neonates and children remains a challenge. The
importance of pharmacokinetic (PK) and pharmacodynamic (PD) research is recognised …

Abstract Background and Objectives Uncertainty exists regarding the optimal dosing
regimen for vancomycin in different patient populations, leading to a plethora of subgroup …

Pharmacokinetic/pharmacodynamic (PKPD) modeling is important in the design and
conduct of clinical pharmacology research in children. During drug development, PKPD …

Consensus guidelines recommend use of granulocyte colony stimulating factor in patients
deemed at risk of chemotherapy‐induced neutropenia, however, these risk models are …

Purpose High-dose methotrexate (HD-MTX) is widely used in pediatric and adult oncology
treatment regimens. This study aimed to develop a population pharmacokinetic model to …

Abstract Background and Objectives Methotrexate (MTX) is widely used for the treatment of
a variety of neoplastic and autoimmune diseases. However, its toxicity and efficacy varied …

Background The aim of this study was to identify sources of variability including patient
gender and body surface area (BSA) in pharmacokinetic (PK) exposure for high-dose …

Treosulfan is given off‐label in pediatric allogeneic hematopoietic stem cell transplant. This
study investigated treosulfan's pharmacokinetics (PKs), efficacy, and safety in a prospective …

Methotrexate (MTX) at a dose of≥ 1 g/m2 remains the most efficient treatment against
primary central nervous system lymphoma (PCNSL), and is the most widely used drug in …